Acquired CRDMO LakePharma is now part of Curia, signaling a broader CRDMO integration. Sales opportunities may arise from cross-sell of integrated Biologics discovery, development, and manufacturing services to Curia’s existing and new clients.

Broad Biologics Capabilities With antibody discovery, protein engineering, cell line development, process optimization, and GMP manufacturing, there are multiple touchpoints for upsell across full-cycle biologics programs, including early discovery to late-stage manufacturing.

Multi‑Coast Footprint Five facilities on both East and West Coasts enable geographically distributed support and rapid project kickoff for US-based biotech customers, presenting nearshore collaboration advantages and regional pricing/timing flexibility.

Moderate Revenue Reported revenue range of 25–50 million with a 30 million funding cushion indicates scalable operations and potential for expansion through larger, multi-program engagements and longer-term CDMO partnerships.

Strategic Partnerships Historical collaborations in vaccine development and ADC workflows (e.g., with Akston, NJ Bio, and in COVID-19 programs) suggest a proven pathway for joint development programs and recapture of end-to-end manufacturing opportunities.